Immortalized pancreatic duct cells in vitro and in vivo

Annals of the New York Academy of Sciences

Volumn 880, Issue , 1999, Pages 50-65

  Jesnowski, R ^a   Muller P ^a   Schareck, W ^a   Liebe, S ^a   Lohr M ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS LARGE T ANTIGEN;

CELL CULTURE; CELL IMMORTALIZATION; CELL PROLIFERATION; CONFERENCE PAPER; DNA TRANSFECTION; EPITHELIUM CELL; HUMAN; HUMAN CELL; ONCOGENE K RAS; PANCREAS DUCT; SIMIAN VIRUS 40; VIRUS CELL TRANSFORMATION;

SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40;

EID: 0032774869     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb09509.x     Document Type: Conference Paper

References (65)

1. 1. BORING, C. et al. 1991. Cancer statistics, 1991. Cancer 41: 19-36.
2. 2. BÜCHLER, M. et al. 1996. Pankreaserkrankungen. S. Karger GmbH. Freiburg.
3. 3. Gordis, L. & E.B. GOLD. 1993. Epidemiology and etiology of pancreatic cancer. In The Pancreas: Biology, Pathobiology and Disease, 2nd Ed. V.L.W. Go et al., Eds,: 837-855. Raven Press. New York.
4. 4. MURR M.M. et al. 1994. Pancreatic cancer. CA Cancer J. Clin. 44: 304-318.
5. 5. SEARLE, P.F. et al. 1996. Gene-transfer therapy and pancreatic cancer. In Pancreatic Cancer. Molecular and Clinical Advances, J.P. Neoptolemos & N.R. Lemoine, Eds. Blackwell Science Ltd. Oxford.
6. 6. KIM, J.H. et al. 1990. Cell lineage markers in human pancreatic cancer. Cancer 66: 2134-2143.
7. 7. BALAGUÉ, C. et al. 1994. Altered expression of MUC2, MUC4, and MUC5 mucin genes in pancreas tissue and cancer cell lines. Gastroenterology 106: 1054-1061.
8. 8. BOUWENS, L. et al. 1994. Cytokeratins as markers of ductal cell differentiation and islet neogenesis in the neonatal rat pancreas. Diabetes 43: 1279-1283.
9. 9. OSBORN, M. et al. 1986. Methods in laboratory investigation. Differential diagnosis of gastrointestínal carcinomas by using monoclonal antibodies specific for individual keratin polypeptides. Lab. Invest. 55: 497-504.
10. 10. SCHUSSLER, M.H. et al. 1992. Intermediate filaments as differentiation markers of normal pancreas and pancreas cancer. Am. J. Pathol. 140: 559-568.
11. 11. SCARPELLI, D.G. et al. 1991. Are acinar cells involved in the pathogenesis of ductal adenocarcinoma of the pancreas? Cancer Cells 3: 275-277.
12. 12. POUR, P.M. 1997. The role of Langethans islets in pancreatic ductal adenocarcinoma. Front Biosci. 2: D271-D282.
13. 13. POUR, P.M. et al. 1997. Experimental evidence for the origin of ductal-type adenocarcinoma from the islets of Langerhans. Am. J. Pathol, 150: 2167-2180.
14. 14. HALL, P.A. et al. 1992. Rapid acinar to ductal transdifferentiation in cultured human exocrine pancreas. J. Pathol. 166: 97-103.
15. 15. VILA, M.R. et al. 1994. Normal human pancreas cultures display functional ductal characteristics. Lab. Invest. 71: 423-431.
16. 16. DABEVA M.D. et al. 1997. Differentiation of pancreatic epithelial progenitor cells into hepatocytes following transplantation into rat liver. Proc. Natl. Acad. Sci. USA 94: 7356-7361.
17. 17. CORNELIUS, J.G. et al. 1997. In vitro-generation of islets in long-term cultures of pluripotent stem cells from adult mouse pancreas. Horm, Metab. Res. 29: 271-277.
18. 18. FERNANDES, A. et al. 1997. Differentiation of new insulin-producing cells is induced by injury in adult pancreatic islets. Endocrinology 138: 1750-1762.
19. 19. ROSENBERG, L. 1995. In vivo cell transformation: Neogenesis of beta cells from pancreatic ductal cells. Cell Transplant. 4: 371-383.
20. 20. MASHIMA, H. et al. 1996. Formation of insulin-producing cells from pancreatic acinar AR42J cells by hepatocyte growth factor. Endocrinology 137: 3969-3976.
21. 21. OHNISHI, H. et al. 1995. Conversion of amylase-secreting rat pancreatic AR42J cells to neuronlike cells by activin A. J. Clin. Invest. 95: 2304-2314.
22. 22. KLÖPPEL, G. 1984. Pancreatic non-endocrine tumors. In Pancreatic Pathology. G. Klöppel & P.U. Heitz, Eds.: 79-113. Churchill Livingstone. Edinburgh.
23. 23. KLÖPPEL, G. 1993, Pathology of nonendocrine pancreatic tumors. In The Pancreas: Biology, Pathobiology, and Disease, 2nd Ed, V.L.W. Go et al., Eds.: 871-897. Raven Press. New York.
24. 24. ALMOGUERA, C, et al. 1988. Most human carcinomas of exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-554.
25. 25. BOS, J.L. 1989. Ras oncogenes in human cancer: A review. Cancer Res. 49: 4682-4689.
26. 26. CAPELL, G. et al. 1996. Molecular epidemiology of protooncogene and tumour-suppressor gene mutations. In Pancreatic Cancer. Molecular and Clinical Advances. J. Neoptolemos & N. Lemoine, Eds.: 169-180. Blackwell Science Ltd. Oxford.
27. 27. LEMOINE, N.R. 1997. Molecular pathology of pancreatic neoplasms. In Biliary and Pancreatic Ductal Epithelia. Pathobiology and Pathophysiology. A.E. Sirica & D.S. Longnecker, Eds.: 505-525. Marcel Dekker. New York.
28. 28. RALL, C, et al. 1996. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma. Pancreas 12: 10-17.
29. 29. BAKER, S.J. et al. 1989. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244: 217-221.
30. 30. KALTHOFF, H. et al. 1993. p53 and k-ras alterations in pancreatic epithelial cell lesions. Oncogene 8: 289-298.
31. 31. MOSKALUK, C.A. et al. 1997. Genomic sequencing of DPC4 in the analysis of familial pancreatic carcinoma. Diagn. Mol. Pathol. 6: 85-90
32. 32. SCHUTTE, M. et al. 1996. DPC4 gene in various tumor types. Cancer Res. 56: 2527-2530.
33. 33. CALDAS, C. et al. 1994. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet. 8: 27-31.
34. 34. HAHN, S. et al. 1997. Neue molekularbiologische Erkenntnisse aus der Pankreaskarzinomforschung. Deutsches frzteblatt. 94: C 2440-C 2446.
35. 35. BARDI, G. et al. 1993. Karyotypic abnormalities in tumours of the pancreas. Br. J. Cancer 67: 1106-1112.
36. 36. GRIFFIN, C. et al. 1994. Chromosome abnormalities in pancreatic adenocarcinoma. Genes Chromosomes Cancer 9: 93-100.
37. 37. KALTHOFF, H. et al. 1993. Cytokine-mediated regulation of growth factor receptors (EGF-R and erb-B2) in pancreatic tumors. In Molecular Diagnostics of Cancer. C. Wagener & S. Neumann, Eds.: 175-186. Springer Verlag. Berlin.
38. 38. LOHR, M. 1996. Zell-und Molekularbiologic der Bindegewebsreaktion bei Pankreatitis und Pankreaskarzinom. Die Gastroenterologische Reihe, Band 32, Solvay, Hannover.
39. 39. FRIESS, H. et al. 1992. Acidic and basic fibroblast growth factors and their receptors are expressed in the human pancreas. Pancreas 7: 737 (abstr.).
40. 40. LEUNG, H.Y. et al. 1994. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int. J. Cancer 59: 667-675.
41. 41. KALTHOFF, H. et al. 1991. Modulation of platelet-derived growth factor A-and B-chain/c-sis mRNA by tumor necrosis factor and other agents in adenocarcinoma cells. Oncogene 6: 1015-1021.
42. 42. KORC, M. 1991. Growth factors and pancreatic cancer. Int. J. Pancreatol. 9: 87-91.
43. 43. LÖHR, M. B. TRAUTMANN, M. GÖTTLER, S. PETERS, I. ZAUNER, B. MAILLET & G. KLÖPPEL. 1994. Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins, Br. J. Cancer 69: 144-151.
44. 44. LÖHR, M., B. TRAUTMANN, M. GÖTTLER, S. PETERS, I. ZAUNER, A. MEIER, G. KLOPPEL G, S. LIEBE & E.D. KREUSER. 1996. Expression and function of receptors for extracellular matrix proteins in human ductal adenocarcinomas of the pancreas. Pancreas 12: 248-259.
45. 45. TRAUTMANN, B. et al. 1993. Isolation, culture, and characterization of human pancreatic duct cells. Pancreas 8: 248-254.
46. 46. JESNOWSKI, R. et al. 1998. Increasing the transfection efficacy of resting pancreatic duct epithelial cells and long term culture of human pancreatic duct epithelial cells. Panreas. In press.
47. 47. AUSUBEL, F.M., R. BRENT, R.E. KINGSTON, J.G. SEIDMAN, J.A. SMITH & K. STRUHL. 1990. Current Protocols in Molecular Biology. Greene Publisher Assoc. Brooklyn, NY. 1994th ed.
48. 48. HELLER, T., B. TRAUTMANN, I. ZÖLLER-UTZ, H.J. KÖNIG, C. ELL, S. LIEBE & M. LÖHR. 1995. Restriktionsenzym-Mismatch-Polymerase-Kettenreaktion zum Nachweis von ki-ras-Onkogen-Mutationen beim Pankreaskarzinom. Dtsche. Med. Wehnsehr. 120: 826-830.
49. 49. CHEN, J.K. et al. 1993. Cyclic AMP-induced inhibition of collagen lattice contraction by fibroblasts may be attenuated by both cyclic AMP dependent and independent mechanisms. J. Cell Physiol. 155: 8-13.
50. 50. MAGNALDO, I. et al. 1989. Cyclic AMP inhibits mitogen-induced DNA synthesis in hamster fibroblasts, regardless of the signalling pathway involved. FEBS Lett. 245: 65-69.
51. 51. TAYLOR-PAPADIMITRIOU, J. et al. 1980. Cholera toxin and analogues of cyclic AMP stimulate the growth of cultured human mammary epithelial cells. J. Cell Physiol. 102: 317-321.
52. 52. HORDIJK, P.L. et al. 1994. cAMP abrogates the p21 ras-mitogen-activated protein kinase pathway in fibroblasts. J. Biol. Chem. 269: 3534-3538.
53. 53. MCKENZIE, F.R. et al. 1996. cAMP-mediated growth inhibition in fibroblasts is not mediated via mitogen-activated protein (MAP) kinase (ERK) inhibition. cAMP-dependent protein kinase induces a temporal shift in growth factor-stimulated MAP kinases. J. Biol. Chem. 271: 13476-13483.
54. 54. MCGUIRE, P.G. et al. 1987. Isolation of rat aortic endothelial cells by primary explant techniques and their phenotypic modulation by defined substrata. Lab. Invest. 57: 94-105.
55. 55. TSAO, M.-S. et al. 1987. Establishment of propagable epithelial cell lines from normal adult rat pancreas. Exp. Cell Res. 168: 365-375.
56. 56. CHENG, R.Z. et al. 1997. Expression of SV40 large T antigen stimulates reversion of a chromosomal gene duplication in human cells. Exp. Cell Res. 234(2): 300-312.
57. 57. GIRARDI, A. et al. 1965. SV40-induced transformation of human diploid cells: crisis and recovery. J. Cell Comp. Physiol. 65: 69-84.
58. 58. TRUCKENMILLER, M.E. et al. 1998. A truncated SV40 large T antigen lacking the p53 binding domain overcomes p53-induced growth arrest and immortalizes primary mesencephalic cells. Cell Tissue Res. 291(2): 175-189.
59. 59. MICHAEL-MICHALOVITZ, D. et al. 1991. Simian virus 40 can overcome the antiproliferative effect of wild-type p53 in the absence of stable large T antigen-p53 binding. J. Virol. 65: 4160-4168.
60. 60. RAY, F.A. et al. 1990. SV40 T antigen alone drives karyotype instability that precedes neoplastic transformation of human diploid fibroblasts. J. Cell Biochem. 42(1): 13-31.
61. 61. REDDEL, R.R. et al. 1995. SV40-induced immortalization and ras-transformation of human bronchial epithelial cells. Int. J. Cancer 61: 199-205.
62. 62. RHIM, J.S. et al. 1994. Stepwise immortalization and transformation of adult human prostate epithelial cells by a combination of HPV-18 and v-Ki-ras. Proc. Natl. Acad. Sci. USA 91: 11874-11878.
63. 63. CAVENDER, J.F. et al. 1995. Simian virus 40 large T antigen contains two independent activities that cooperate with a ras oncogene to transform rat embryo fibroblasts. J. Virol. 69: 923-934.
64. 64. KORC, M. 1998. Role of growth factors in pancreatic cancer. S. Oncol. Clin. N. Am. 7: 25-41.
65. 65. BODNAR, A. et al. 1998. Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349-352.